1213446-52-6

Usage

Uses

Used in Pharmaceutical Industry:
(S)-(4-(1-AMINOETHYL)PHENYL)METHANOL is used as a synthetic precursor for the creation of new drug candidates due to its ability to be incorporated into various molecular structures, enhancing the development of innovative therapeutic agents.
Used in Biochemical Research:
In the field of biochemical research, (S)-(4-(1-AMINOETHYL)PHENYL)METHANOL is utilized as a key component in the study of biological processes and pathways, providing insights into the mechanisms of action and potential interactions with biological targets.
Used in Drug Discovery:
(S)-(4-(1-AMINOETHYL)PHENYL)METHANOL is employed as a valuable tool in drug discovery, leveraging its unique structure and properties to identify and optimize potential therapeutic agents, thereby contributing to advances in medicinal chemistry.

Upstream product

• 885105-34-0 (R)-methyl 4-(1-azidoethyl)benzoate 
• 1021491-26-8 tert-butyl N-[(1R)-1-[4-(hydroxymethyl)phenyl]ethyl]carbamate 
• 222714-37-6 4-[(1S)-1-aminoethyl]-benzoic acid, methyl ester 
• 1211572-03-0 tert-butyl (1-(4-(hydroxymethyl)phenyl)ethyl)carbamate 
• 80051-07-6 4-carbomethoxy-α-methylbenzylamine 
• 79322-76-2 methyl 4-[(1S)-1-hydroxyethyl]benzoate 
• 3609-53-8 methyl 4-acetylbenzoate 

Downstream Products

• 1021491-24-6 {4-[(1R)-1-aminoethyl]phenyl}methanol hydrochloride 

Relevant academic research and scientific papers

7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIT USE AS MUTANT IDH1 INHIBITORS

Phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds of Formula I, formulations containing those compounds, and their use as mutant isocitrate dehydrogenase 1 enzyme inhibitors.

SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS

This invention provides a compound of the formula (I). These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical compo

NEW BRADYKININ B1 ANTAGONISTS

The invention relates to compounds of formula (I) where in R1, R1a, R1b, R2, R3 and X, X1, X2, X3 have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES

The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X1, X2, X3, and X4, which may be identical or different, are each C or N, provided that none to two of X1, X2, X3, and X4 is/are N; Y is CH or N; R1, R1', R2, R2', R3, R3', R4, and R4', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R5 is a hydrogen atom or a methyl group; R6 and R7, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R8 and R8', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.

Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity

We report the discovery of chroman 28, a potent and selective antagonist of human, nonhuman primate, rat, and rabbit bradykinin B1 receptors (0.4-17 nM). At 90 mg/kg s.c., 28 decreased plasma extravasation in two rodent models of inflammation. A novel met